1. Immune profiling of patient-derived organotypic tumor spheroids.
Immune profiling of patient-derived organotypic tumor spheroids. A, Immune profiling of PDOTS (S2; n = 40; top = % live cells; bottom = %CD45+ cells) with indicated patient/tumor characteristics, grouped by tumor type and ranked by %CD8+ T cells. *, DFCI-13, 16, 18, 21, and 22 represent serial pleural effusion samples from same patient; **, MGH-04 and 07 are serial biopsies from the same patient; #, DFCI-02 and 17 are samples from same patient; ∧, DFCI-10 and 29 are samples from the same patient; ∞, MGH-12 and 14 are serial samples from a patient with a brain metastasis requiring resection and subsequent re-resection. HNSCC, head and neck squamous cell carcinoma. B and C, Immunofluorescence staining identifying (B) CD45+ immune cells and (C) CD8+ T cells with EpCAM+ cancer cells non–small cell lung cancer (NSCLC) PDOTS. D, Immune cell correlation of S2/S3 fractions (CD45, n = 14; CD3, n = 15; CD4/CD8, n = 13; CD4+CD45RO+, n = 9; CD8+CD45RO+, n = 8; activated = CD38+ and/or CD69+, n = 6), R2 significant for all comparisons. E, PD-1, CTLA4, and TIM3 expression on CD4 and CD8 T-cell populations in S2/S3 fractions (n = 6), R2 significant for all comparisons.
Russell W. Jenkins et al. Cancer Discov 2018;8:
©2018 by American Association for Cancer Research